Edition:
United States

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
26 Apr 2018
Change (% chg)

$0.02 (+2.15%)
Prev Close
$0.93
Open
$0.90
Day's High
$0.96
Day's Low
$0.90
Volume
12,075
Avg. Vol
16,466
52-wk High
$3.00
52-wk Low
$0.90

Chart for

About

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $50.89
Shares Outstanding(Mil.): 21.20
Dividend: --
Yield (%): --

Financials

  TTNP.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.54 -- --
ROI: -85.18 14.84 14.38
ROE: -90.44 16.34 16.07

BRIEF-Titan Pharmaceuticals Q4 Loss Per Share $0.17

* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Apr 02 2018

BRIEF-Titan Pharmaceuticals Executes Agreement For Acquisition By Molteni Of Probuphine In Europe And Other Territories

* TITAN EXECUTES AGREEMENT FOR ACQUISITION BY MOLTENI OF PROBUPHINE® IN EUROPE AND OTHER SELECT TERRITORIES

Mar 21 2018

BRIEF-Titan Announces Amendment To Horizon Loan Agreement

* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION

Feb 02 2018

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

Nov 28 2017

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

Nov 28 2017

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

Nov 27 2017

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

Nov 09 2017

Earnings vs. Estimates